Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease (label: moderately to severely active CD or UC who have had an inadequate response with, lost response to,...), Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
JP
  • Moderately to severely active ulcerative colitis: IV induction, SC maintenance, where existing therapy is inadequatenk.jiho.jp
  • Moderately to severely active Crohn's disease: IV 130 mg induction (new) and SC 45 mg syringe maintenance (indication added)nk.jiho.jp
Product first approved 2017
UK
  • Moderately to severely active Crohn's disease and ulcerative colitis
Product first approved 2016medicines.org.uk
EU
  • Moderate to severe plaque psoriasis in adults (initial EU authorisation; PsA, Crohn's and UC added later)
Product first approved 2009EMA
CA
  • Plaque Psoriasis Stelara (ustekinumab) is indicated for: • the treatment of chronic moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy • the treatment of chronic moderate to severe plaque psoriasis in pediatric patients (6-17 years of age) who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see 1.1 Pediatrics). Psoriatic Arthritis Stelara (ustekinumab) is indicated for the treatment of adult patients with active psoriatic arthritis. Stelara can be used alone or in combination with...
Product first approved 2008Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (39)
Crohn's Disease
NCT05299931 · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
2021-09-10 – 2026-05-29 · Crohn Disease
What this study did
Psoriasis
NCT04607980 · Amgen
2020-11-11 – 2022-06-03 · Plaque Psoriasis
What this study did
NCT02203032 · Janssen Research & Development, LLC
2014-10-07 – 2016-05-24 · Psoriasis
What this study did
NCT01550744 · Janssen Biotech, Inc.
2012-03 – 2015-07 · Psoriasis
What this study did
NCT01090427 · Janssen Research & Development, LLC
2010-05 – 2014-01 · Psoriasis
What this study did
NCT01091051 · Innovaderm Research Inc.
2010-03 – 2011-11 · Palmo-Plantar Pustular Psoriasis, Palmo-Plantar Pustulosis
What this study did
NCT01008995 · Centocor, Inc.
2009-10 – 2011-07 · Psoriasis
What this study did
NCT00723528 · Janssen Pharmaceutical K.K.
2008-03 – 2010-03 · Psoriasis
What this study did
NCT00454584 · Centocor, Inc.
2007-03 – 2009-01 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05092269 · Janssen Research & Development, LLC
2021-10-18 – 2028-03-15 · Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
What this study did
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT04632927 · Novartis Pharmaceuticals
2020-12-21 – 2024-10-22 · Psoriatic Arthritis
What this study did
NCT03148860 · Dr. Frank Behrens
2016-12-15 – 2021-10-21 · Psoriatic Arthritis
What this study did
Ulcerative Colitis
Other / comorbidity
NCT04060888 · Janssen Research & Development, LLC
2020-07-14 – 2026-03-31 · Lupus Erythematosus, Systemic
What this study did
NCT04882072 · Janssen Pharmaceutical K.K.
2021-09-15 – 2023-05-25 · Takayasu Arteritis
What this study did
NCT04089345 · Universitaire Ziekenhuizen KU Leuven
2020-06-15 – 2023-05-01 · Pouchitis
What this study did
NCT03981744 · Janssen Pharmaceutical K.K.
2019-07-26 – 2022-07-12 · Polymyositis, Dermatomyositis
What this study did
NCT03517722 · Janssen Research & Development, LLC
2018-04-16 – 2020-11-05 · Lupus Erythematosus, Systemic
What this study did
NCT02407223 · Janssen Research & Development, LLC
2015-07-13 – 2017-09-26 · Nonradiographic Axial Spondylitis, Ankylosing
What this study did
NCT02437162 · Janssen Research & Development, LLC
2015-09-03 – 2017-09-06 · Axial Spondyloarthritis
What this study did
NCT02438787 · Janssen Research & Development, LLC
2015-07-31 – 2017-08-31 · Axial Spondyloarthritis
What this study did
Phase 2/3 (3)
Crohn's Disease
NCT03466411 · Janssen Research & Development, LLC
2018-04-13 – 2028-01-28 · Crohn's Disease
What this study did
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT03941132 · University of British Columbia
2021-01-04 – 2026-11-01 · Type 1 Diabetes Mellitus
What this study did
Phase 2 (31)
Crohn's Disease
NCT04655807 · Janssen Research & Development, LLC
2021-03-03 – 2023-09-04 · Crohn Disease
What this study did
NCT02877134 · Janssen Research & Development, LLC
2016-08-25 – 2022-01-24 · Crohn Disease
What this study did
NCT00265122 · Centocor, Inc.
2004-04 – 2006-10 · Crohn Disease
What this study did
Psoriasis
NCT03553823 · Novartis Pharmaceuticals
2019-01-14 – 2020-01-28 · Chronic Plaque-type Psoriasis
What this study did
NCT00320216 · Centocor, Inc.
2003-11 – 2005-03 · Psoriasis
What this study did
Psoriatic Arthritis
NCT03881059 · Bristol-Myers Squibb
2019-04-01 – 2021-01-27 · Active Psoriatic Arthritis
What this study did
NCT02319759 · Janssen Research & Development, LLC
2015-03-27 – 2017-01-17 · Psoriatic Arthritis
What this study did
NCT00267956 · Centocor, Inc.
2005-12 – 2007-09 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT07268534 · Assistance Publique - Hôpitaux de Paris
2026-04-01 – 2030-04-01 · Folliculitis Decalvans (FD)
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT04572815 · Fred Hutchinson Cancer Center
2021-05-14 – 2027-06-30 · Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
What this study did
NCT06807593 · M.D. Anderson Cancer Center
2026-02-24 – 2027-03-31 · Cancer
What this study did
NCT07582991 · Liu Tian
2024-03-24 – 2026-02-23 · Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome
What this study did
NCT03651518 · Assistance Publique - Hôpitaux de Paris
2020-10-20 – 2025-11-20 · Inflammatory Disease, Autoimmune Diseases
What this study did
NCT03711448 · Centre Hospitalier Universitaire Dijon
2019-01-07 – 2024-09-11 · Patients Relapsing Refractory Giant Cell Arteritis
What this study did
NCT03847272 · Centre Hospitalier Universitaire Dijon
2019-08-01 – 2023-10-25 · Patients With Newly Diagnosed Active NISU
What this study did
NCT04117932 · CHU de Reims
2020-03-11 – 2023-06-22 · Bullous Pemphigoid
What this study did
NCT02911116 · National Eye Institute (NEI)
2017-03-30 – 2020-05-28 · Uveitis
What this study did
NCT02648581 · Assistance Publique - Hôpitaux de Paris
2017-06-14 – 2019-11-19 · Behçet Disease
What this study did
NCT02349061 · Janssen Research & Development, LLC
2015-10-15 – 2019-03-13 · Lupus Erythematosus, Systemic
What this study did
NCT01713400 · H. Lee Moffitt Cancer Center and Research Institute
2013-02-25 – 2018-06-14 · Graft vs. Host Disease
What this study did
NCT02204397 · Jewish General Hospital
2015-11 – 2017-03-08 · Type 1 Diabetes Mellitus
What this study did
NCT01806662 · Rockefeller University
2013-03 – 2015-03 · Atopic Dermatitis
What this study did
NCT01945086 · Janssen Pharmaceutical K.K.
2013-09 – 2014-12 · Dermatitis, Atopic
What this study did
NCT01704534 · University Medical Center Groningen
2012-05 – 2014-04 · Hidradenitis Suppurativa
What this study did
NCT01389973 · Janssen Research & Development, LLC
2011-09 – 2013-06 · Primary Biliary Cirrhosis
What this study did
NCT01330901 · Charite University, Berlin, Germany
2011-10 – 2013-05 · Ankylosing Spondylitis
What this study did
NCT00207727 · Centocor, Inc.
2004-07 – 2006-08 · Multiple Sclerosis
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT03366142 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-07-02 – 2024-10-17 · LAD1
What this study did
NCT02199496 · National Institute of Allergy and Infectious Diseases (NIAID)
2015-10-19 – 2020-07-10 · Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
What this study did
NCT02955147 · Massachusetts General Hospital
2016-12-01 – 2019-09-19 · Giant Cell Arteritis, Temporal Arteritis, Horton's Disease
What this study did
NCT02117765 · University of British Columbia
2015-03 – 2017-06 · Type 1 Diabetes
What this study did
NCT01647152 · National Eye Institute (NEI)
2012-07-03 – 2015-06-30 · Uveitis
What this study did
Phase 1 (16)
Crohn's Disease
NCT05725876 · University Medical Center Groningen
2025-01-06 – 2027-01-06 · Psoriasis, Crohn Disease
What this study did
NCT02968108 · Janssen Research & Development, LLC
2017-01-18 – 2022-03-18 · Crohn Disease
What this study did
Psoriasis
NCT04744363 · Alvotech Swiss AG
2021-05-25 – 2022-03-19 · Psoriasis
What this study did
NCT02763969 · Bristol-Myers Squibb
2016-05-18 – 2016-12-15 · Psoriasis
What this study did
NCT01276847 · Merck Sharp & Dohme LLC
2011-03 – 2011-12 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05252533 · Janssen Research & Development, LLC
2022-05-24 – 2024-01-26 · Juvenile Psoriatic Arthritis, Psoriasis, Arthritis, Juvenile
What this study did
Ulcerative Colitis
NCT06742606 · Ain Shams University
2025-01-15 – 2026-12-13 · Effect of Drug
What this study did
NCT03358706 · Janssen Research & Development, LLC
2018-02-02 – 2021-11-22 · Crohn Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT04549792 · Northwestern University
2021-04-01 – 2024-06-26 · Ichthyosis
What this study did
NCT04093531 · University of Rochester
2020-01-15 – 2022-05-11 · Primary Sjögren Syndrome
What this study did
NCT04816513 · Janssen Research & Development, LLC
2021-04-14 – 2022-01-26 · Healthy
What this study did
NCT04030533 · Janssen Research & Development, LLC
2019-11-29 – 2020-12-31 · Healthy
What this study did
NCT02156375 · Janssen Research & Development, LLC
2014-05 – 2014-12 · Healthy
What this study did
NCT01081704 · Centocor, Inc.
2009-10 – 2010-06 · Healthy
What this study did
Phase 4 (19)
Crohn's Disease
NCT06520397 · Sixth Affiliated Hospital, Sun Yat-sen University
2024-07-15 – 2027-07-31 · Crohn Disease
What this study did
NCT06045754 · Takeda
2024-04-18 – 2027-06-28 · Crohn's Disease
What this study did
NCT04496063 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2020-11-16 – 2025-12-30 · Crohn's Disease
What this study did
NCT05029921 · Janssen Research & Development, LLC
2021-12-10 – 2025-05-18 · Crohn Disease
What this study did
NCT05861167 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-06-01 – 2024-06-01 · Crohn Disease
What this study did
NCT04629196 · NYU Langone Health
2022-02-16 – 2024-01-17 · Crohn Disease
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT05270733 · University Hospitals Cleveland Medical Center
2022-11-10 – 2026-12-31 · Psoriasis
What this study did
NCT02144857 · University of Athens
2014-05-30 – 2023-12-31 · Psoriasis
What this study did
NCT02187172 · University of Pennsylvania
2014-07 – 2018-09-11 · Psoriasis, Cardiovascular Disease
What this study did
NCT02693470 · Chang Gung Memorial Hospital
2014-08 – 2016-07 · Psoriasis With Cell-derived Microparticles
What this study did
NCT01511315 · University of California, San Francisco
2012-03 – 2014-12 · Psoriasis
What this study did
NCT01558310 · Paul Steven Yamauchi, MD, PhD
2012-08 – 2013-12 · Scalp Psoriasis, Plaque Psoriasis
What this study did
NCT01059773 · Janssen-Cilag International NV
2009-10 – 2011-08 · Psoriasis
What this study did
Ulcerative Colitis
NCT07576452 · University Hospital, Clermont-Ferrand
2026-12-01 – 2030-12-01 · Ulcerative Colitis (UC)
What this study did
NCT06788340 · Odense University Hospital
2026-01-23 – 2028-11-30 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
NCT07303686 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2025-10-08 – 2027-10-15 · Crohn Disease (CD), Ulcerative Colitis (UC)
What this study did
NCT03629379 · Universitaire Ziekenhuizen KU Leuven
2019-01-22 – 2021-07-01 · Inflammatory Bowel Diseases, Psoriasis
What this study did
Other / comorbidity
NCT04996485 · National Medical Research Center for Children's Health, Russian Federation
2021-03-01 – 2023-06-01 · Congenital Ichthyosis
What this study did
Early phase / not applicable (8)
Crohn's Disease
NCT06912815 · Xiang Gao
2024-08-01 – 2026-09 · Crohn Disease (CD)
What this study did
NCT04779762 · Wolfson Medical Center
2022-01 – 2026-01 · Crohn Disease
What this study did
NCT06455267 · The Third Xiangya Hospital of Central South University
2024-04-01 – 2025-09-30 · Mild to Severe Crohns Disease
What this study did
NCT04795960 · University of Michigan
2021-03-18 – 2023-03 · Crohn Disease
What this study did
NCT03712826 · Hospices Civils de Lyon
2022-07-24 – 2022-07-24 · Crohn Disease
What this study did
Psoriasis
NCT01090063 · Tufts Medical Center
2010-02 – 2012-04 · Moderate to Severe Palmar Plantar Psoriasis
What this study did
NCT00870285 · Medical University of Graz
2009-03 – 2011-04 · Psoriasis
What this study did
Ulcerative Colitis
NCT07529236 · Centre Hospitalier Universitaire de Nice
2026-04-20 – 2027-10-01 · Chronic Inflammatory Bowel Diseases
What this study did
Used as active comparator (33)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (25)
Crohn's Disease
NCT07149467 · Sixth Affiliated Hospital, Sun Yat-sen University
2025-09-10 – 2027-12-31 · Crohn's Disease Aggravated, Crohn's Disease in Remission
What this study did
NCT03926130 · Eli Lilly and Company
2019-07-23 – 2023-10-02 · Crohn's Disease
What this study did
Psoriasis
NCT07116967 · Bristol-Myers Squibb
2025-09-22 – 2031-01-16 · Plaque Psoriasis
What this study did
NCT06425549 · UCB Biopharma SRL
2024-06-25 – 2030-11-08 · Moderate to Severe Plaque Psoriasis
What this study did
NCT06934226 · Janssen Research & Development, LLC
2025-04-15 – 2027-08-20 · Plaque Psoriasis
What this study did
NCT06488664 · AO GENERIUM
2023-07-25 – 2025-11-26 · Plaque Psoriasis
What this study did
NCT05335356 · Biocon Biologics UK Ltd
2022-06-28 – 2023-11-15 · Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT04728360 · Bio-Thera Solutions
2021-07-06 – 2023-07-07 · Plaque Psoriasis
What this study did
NCT04305327 · LEO Pharma
2022-12-07 – 2023-05-05 · Psoriasis
What this study did
NCT04967508 · Samsung Bioepis Co., Ltd.
2021-07-06 – 2022-11-25 · Psoriasis, Moderate to Severe Plaque Psoriasis
What this study did
NCT04785326 · Dong-A ST Co., Ltd.
2021-04-28 – 2022-11-16 · Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT04930042 · Alvotech Swiss AG
2021-06-03 – 2022-10-11 · Psoriasis
What this study did
NCT04673786 · Celltrion
2021-01-11 – 2022-05-12 · Psoriasis
What this study did
NCT02826603 · Novartis Pharmaceuticals
2016-06-22 – 2018-07-09 · Plaque Psoriasis
What this study did
NCT02786732 · MedDerm Associates
2012-08 – 2017-10 · Psoriasis
What this study did
NCT02561806 · Eli Lilly and Company
2015-10 – 2017-10 · Plaque Psoriasis
What this study did
NCT02684357 · AbbVie
2016-03 – 2017-09 · Psoriasis
What this study did
NCT02074982 · Novartis Pharmaceuticals
2014-02-26 – 2016-06-29 · Chronic Plaque Type Psoriasis
What this study did
NCT01708603 · Bausch Health Americas, Inc.
2012-08 – 2015-10 · Moderate to Severe Plaque Psoriasis
What this study did
NCT01708629 · Bausch Health Americas, Inc.
2012-09 – 2015-10 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT03370133 · UCB Biopharma SRL
2017-12-06 – 2019-12-13 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
What this study did
Ulcerative Colitis
NCT07177118 · First Affiliated Hospital of Wenzhou Medical University
2025-10-20 – 2028-10-20 · Crohn Disease, Crohn Disease and Ulcerative Colitis
What this study did
Phase 2 (2)
Psoriasis
NCT02054481 · Boehringer Ingelheim
2014-02 – 2015-07 · Psoriasis
What this study did
Ulcerative Colitis
NCT06453317 · Medical University of Lodz
2025-02-17 – 2028-06-30 · Ulcerative Colitis, Inflammatory Bowel Diseases
What this study did
Phase 1/2 (1)
Crohn's Disease
NCT03167437 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-10-30 – 2035-06-30 · Crohn's Disease
What this study did
Phase 1 (5)
Psoriasis
NCT04843631 · BioFactura Australia Pty Ltd.
2021-04-01 – 2021-12-08 · Psoriasis
What this study did
NCT04371185 · Bio-Thera Solutions
2020-08-08 – 2021-04-19 · Psoriasis
What this study did
Other / comorbidity
NCT05890118 · RANI Therapeutics
2023-08-30 – 2023-11-28 · Healthy Volunteers
What this study did
NCT06481215 · AO GENERIUM
2022-03-11 – 2022-12-20 · Healthy Volunteers
What this study did
NCT04428814 · Celltrion
2020-08-03 – 2021-02-24 · Healthy Subjects
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Psoriasis
NCT04761627 · Amgen
2021-03-24 – 2023-02-28 · Psoriasis
What this study did
Phase 2 (2)
Crohn's Disease
NCT04978493 · Boehringer Ingelheim
2021-12-02 – 2024-08-08 · Crohn Disease
What this study did
Psoriasis
NCT01999868 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-03-19 – 2018-03-01 · Psoriasis
What this study did
Phase 4 (2)
Crohn's Disease
NCT05928039 · University of Calgary
2023-10-25 – 2028-12-31 · Crohn Disease
What this study did
Ulcerative Colitis
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Ulcerative Colitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ustekinumab (Stelara): this drugApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV)
NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders.
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo)
NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001).
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Balsalazide Disodium (Colazal)
ApprovedUS marketing discontinued
Small moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Budesonide MMX (Uceris)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Etrasimod (Velsipity)ApprovedSmall moleculeS1P receptorReliable signal
NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo)
NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4)
NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance)
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8)
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Hydrocortisone (Cortenema)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaWeak signal
NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%)
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Apriso)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Canasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Lialda)ApprovedSmall moleculeAminosalicylateReliable signal
NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants
Mesalamine (Pentasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Rowasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5)
NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W)
Olsalazine (Dipentum)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorReliable signal
NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period))
NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo.
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
INSPIRE/COMMAND: clinical remission + endoscopic improvement met
NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV)
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Reliable signal
NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo)
NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo)
NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg)
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinReliable signal
NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg)
NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
Mesalamine (Asacol HD)US approval withdrawnSmall moleculeAminosalicylatePartial signalNo reviewed efficacy summary in this indication
AfimkibartPhase 3Monoclonal antibodyTL1APartial signal
NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptorReliable signal
NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001)
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 3Small moleculemiR-124Reliable signal
NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001
NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%)
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1AReliable signal
NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints.
NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37)
AC-101Phase 2Small moleculeRIPK2not yet gradedNo reviewed efficacy summary in this indication
ALTB-268Phase 2Monoclonal antibodyPSGL-1Weak signalNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorReliable signal
NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002)
ATH-063Phase 2Small moleculeG9A (EHMT2)Weak signalFeatured results are safety only in this race
BI 3032950Phase 2Monoclonal antibodyTREM-1not yet gradedNo reviewed efficacy summary in this indication
CU104Phase 2Small moleculeEndothelial barrier functionPartial signalNo reviewed efficacy summary in this indication
GarutadustatPhase 2Small moleculePHD1/2not yet gradedNo reviewed efficacy summary in this indication
HRS-7085Phase 2Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
HSK47388Phase 2PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
IPG11406Phase 2Small moleculeEBI2Weak signalFeatured results are safety only in this race
Live SK08Phase 2Microbiome therapeuticLive biotherapeutic productnot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Nomelcitinib (D-2570)Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 2Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2Partial signal
NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7%
PALI-2108Phase 2Small moleculePDE4Weak signalFeatured results are safety only in this race
PicankibartPhase 2Monoclonal antibodyIL-23 p19Partial signal
NCT05377580: Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05).
ZotemtegrastPhase 2Small moleculeα4β7 integrinWeak signal
NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed
NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18)
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 1/2Cell therapyAllogeneic MSC therapynot yet gradedNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ExoFloPhase 1Cell therapyMSC-derived exosomesWeak signalNo reviewed efficacy summary in this indication
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
R-3750Phase 1Biologic (subtype unspecified)Dendritic cell targetingnot yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 82 furthest-along competitors are listed; 32 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Stelara (ustekinumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06520397 · CT.gov ↗
What to watch
Phase 4PsoriasisRecruiting
Est. primary completion 2026-12-31 · NCT05270733 · CT.gov ↗
What to watch
2027 (7)
January 2027 (1)
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2CancerRecruiting
Est. primary completion 2027-03-31 · NCT06807593 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-04-15 · NCT07303686 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4Crohn's DiseaseActive not recruiting
Est. primary completion 2027-06-28 · NCT06045754 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Psoriatic ArthritisActive not recruiting
Est. primary completion 2027-09-29 · NCT05092269 · CT.gov ↗
What to watch
October 2027 (1)
Early phase / not applicablePsoriasisRecruiting
Est. primary completion 2027-10-01 · NCT07529236 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Crohn's DiseaseEnrolling by invitation
Est. primary completion 2027-12-30 · NCT06788340 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
Phase 2Folliculitis Decalvans (FD)Not yet recruiting
Est. primary completion 2029-11-01 · NCT07268534 · CT.gov ↗
What to watch
2030 (2)
June 2030 (2)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07576452 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026ApprovalFDA approves Stelara for pediatric ulcerative colitis
US, FDA · Janssen · Source ↗
15 April 2026ApprovalFDA approves Stelara for pediatric Crohn's disease
US, FDA · Johnson & Johnson · Source ↗